The transcriptional repressor DREAM is a member of a Ca 2+ -binding family that contains four Ca 2+ -binding motifs (EF hands) that interact as a tetramer with downstream regulatory elements (DREs) to inhibit transcription 1 . Ca 2+ signaling has been linked to the activation of DREAM because a decrease in the intracellular concentration of Ca 2+ increases the affinity with which DREAM binds to DREs and thereby transcriptionally represses the target genes 1 . The binding of DREAM to DREs is reversed by activation of protein kinase A by cAMP through phosphorylation of the DREAM-interacting protein α-CREM, which blocks the binding of DREAM to DREs 2,3 . DREAM is involved in sensing pain 4,5 , a hallmark of inflammation. DREAM is expressed in pain-sensing areas of the spinal cord in association with κ-opiate receptors 4,5 , but it is also present in cells of the immune system, such as T lymphocytes and B lymphocytes 6, 7 , in which its function is not understood. Mice with transgenic expression of a dominant-active DREAM mutant show markedly reduced production of the cytokines interleukin 2 (IL-2), IL-4 and interferon-γ, increased B cell numbers and decreased production of immunoglobulin G 6,7 . As activation of the transcription factor NF-κB may regulate some of those responses, we surmised that DREAM might be involved in the mechanism of inflammation through its ability to control NF-κB signaling. In addition to the transcription-repressive function of DREAM, the transcription factor USF1, which binds to the E-box domain associated with DREs on the promoter of the gene encoding the deubiquitinase A20, is also involved in initiating transcription of that gene 8 . The question arises, therefore, of whether DREAM and USF1 function cooperatively to coordinate transcription of the gene encoding A20 and thus the magnitude of proinflammatory NF-κB signaling.
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NF-κB is composed of dimers of five proteins (p50, p52, p65 (RelA), RelB and c-Rel) that exist in an inactive form in the cytoplasm bound to three inhibitory proteins (IκBα, IκBβ and IκBε) [9] [10] [11] . Activation of NF-κB in the classical pathway requires activation of the IκB kinase (IKK) complex, which contains the kinases IKKα and IKKβ and the regulatory protein IKKγ 9 . Activated IKK complexes phosphorylate IκBα and IκBβ, which leads to their proteolytic degradation and frees NF-κB dimers to translocate to the nucleus to induce the expression of various target genes. Signaling via Toll-like receptors, the receptor for IL-1, the receptor for tumor-necrosis factor (TNF) and G proteincoupled receptors induces the activation of IKK complexes, which results in NF-κB activity [9] [10] [11] [12] . The identification of feedback checks on NF-κB activation has been of great interest as possible drug targets. A key downregulator of NF-κB is A20 (ref. 13) , first identified as an antiapoptotic protein in human umbilical vein endothelial cells 14 . NF-κB induces A20 expression within hours of being activated by TNF or lipopolysaccharide (LPS) [15] [16] [17] . A20 in turn inhibits the functions of the transcription factors TRAF2, TRAF5 and TRAF6, the adaptor RIP1, the effector RIP2, and IKKγ upstream of IKK complexes by editing ubiquitin chains on those proteins essential for IKK activation [15] [16] [17] [18] [19] [20] [21] . The ovarian tumor domain of A20 mediates the deubiquitination of Lys63 (K63)-linked polyubiquitinated proteins, and the carboxy (C)-terminal zinc finger domain of A20 has ubiquitin ligase activity that mediates K48-linked polyubiquitination of target proteins to induce their proteasomal degradation and terminate NF-κB signaling 19, 20 . A20-deficient mice develop spontaneous inflammation and cachexia and die prematurely 22 . Targeted cardiac overexpression of A20 improves outcome in a mouse model of myocardial infarction by suppressing inflammation 23 . A20 overexpression is also protective in a mouse model of atherosclerosis, whereas haploinsufficiency in A20 results in severe atherosclerosis 24 . Such studies underscore the importance of A20 in restricting inflammation. However, the transcriptional mechanisms of A20 expression are poorly understood. Therefore, to gain insight into those mechanisms, we analyzed the promoter of the gene encoding A20 and detected DREAM-binding DREs both upstream and downstream of the transcription start site (TSS) in intron 1 of human and mouse genes encoding A20. In addition, we found that the E-box domain was an integral component of DREs. Further, we observed that both basal and endotoxin-induced A20 expression in endothelial cells and macrophages was markedly augmented in mice deficient in DREAM (Kcnip3 −/− ; called 'Dream −/− ' here), which in turn prevented the activation of NF-κB signaling. Production of the inflammatory cytokines IL-6, MCP-1 and TNF, the sequestration of polymorphonuclear neutrophils (PMNs) in the lungs and expression of the integrin ligand ICAM-1 were also suppressed in response to endotoxin in Dream −/− mice, and their survival was much greater than that of wild-type mice.
RESULTS

DREAM mediates inflammatory lung injury and mortality
We first assessed the expression of ICAM-1, pathological changes in lungs, and lung myeloperoxidase (MPO) activity (an indicator of PMN sequestration) in wild-type and Dream −/− mice at various times after intraperitoneal injection of LPS (10 mg per kg body weight). LPS induced severe lung injury and sequestration of PMNs in the lungs and increased expression of ICAM-1 protein in a time-dependent manner in wild-type mice, whereas those responses were significantly reduced in Dream −/− mice (Fig. 1a-c) . To quantify changes in lung vascular permeability (an index of inflammatory injury), we measured the pulmonary microvessel filtration coefficient. LPS significantly increased this value in wild-type lungs, whereas deletion of DREAM abrogated this response (Fig. 1d) . We also observed considerably fewer PMNs and less MPO activity in bronchoalveloar lavage fluid (BALF) from Dream −/− mice than in that from wild-type mice (Fig. 1e) . In addition, in response to LPS, concentrations of the proinflammatory mediators IL-6, MCP-1 and TNF in BALF from Dream −/− mice were lower than those in BALF from wild-type mice (Fig. 1f) . In survival studies, 90% of wild-type mice died within 6 d of LPS administration, whereas only 50% of Dream −/− mice died during the same period, and thereafter there were no further deaths (Fig. 1g) . To confirm the findings reported above in a severe model of sepsis, we used cecal ligation and puncture (CLP) to induce polymicrobial sepsis in age-, sex-and weight-matched wild-type and Dream −/− mice. In these studies, we noted 100% mortality in wildtype mice within 36 h of CLP, whereas only 20% of Dream −/− mice died in the same period (Fig. 1h) ; 50% of Dream −/− mice were alive 3 d after CLP, and 40% remained alive more than 2 weeks after CLP (Fig. 1h) . 
A r t i c l e s
To determine whether DREAM deficiency in hematopoietic cells, rather than its deficiency in nonhematopoietic cells such as endothelial cells (which consitute ~50% of the total lung cell population 25 ) and epithelial cells, was responsible for the attenuation of inflammation in Dream −/− mice, we transplanted wild-type mouse bone marrow (BM) cells into lethally irradiated Dream −/− mice 26 . We used those chimeras (WT-BM→Dream −/− ) for experiments 6 weeks after transplantation. Analysis of the male-specific Sry gene in DNA isolated from blood cells of recipient mice showed highly efficient reconstitution of wild-type bone marrow ( Supplementary  Fig. 1a) . After challenging wild-type, Dream −/− and WT-BM→ Dream −/− mice similarly with LPS, we found that sequestration of PMNs in the lungs, the presence of chemokines and cytokines (MCP-1, IL-6 and TNF) in BALF and the expression of ICAM-1 in the lungs of WT-BM→Dream −/− mice were not substantially different from that of Dream −/− mice ( Supplementary Fig. 1b-d,f) . After LPS challenge, the concentrations of MCP-1, IL-6 and TNF in serum from WT-BM→Dream −/− mice were not substantially different from those in serum from wild-type mice ( Supplementary  Fig. 1e) . However, the concentration of MCP-1 in serum from LPS-treated Dream −/− mice was substantially lower than that of their wild-type counterparts (Supplementary Fig. 1e ), which suggested that unlike the changes in the serum concentrations of IL-6 and TNF, the main source of MCP-1 was hematopoietic cells; this finding was consistent with a study showing that MCP-1 is generated mainly by hematopoietic cells 27 . The mortality of WT-BM→ Dream −/− mice resembled that of Dream −/− mice ( Supplementary  Fig. 1f) . These results together suggested that DREAM signaling in hematopoietic cells was not responsible for the full-blown inflammatory lung-injury response.
DREAM and USF1 coordinate A20 transcription We observed that LPS-induced inflammatory responses were attenuated in Dream −/− mice; however, the mechanism for the attenuation of inflammation in Dream −/− mice remained unclear. Since DREAM represses target genes by binding to DREs, we sought to determine whether DREAM represses A20, resulting in inflammation. Thus, we analyzed the 5′ regulatory region of the human gene encoding A20 (TNFAIP3) and identified the presence of DREAM-binding DRE sites (sequence, GTCA) downstream of the TSS in intron 1, and three additional DRE sites upstream of the TSS (Fig. 2a) . One of those sites, DRE3, had an overlapping E-box sequence (Fig. 2a) .
We used chromatin immunoprecipitation (ChIP) to assess the binding of DREAM to DREs in the TNFAIP3 promoter in human lung microvessel endothelial cells and observed basal binding of DREAM to DRE3 and DRE4 in the TNFAIP3 promoter ( Fig. 2b-e) , consistent with the transcription-repressing function of DREAM. In contrast to the binding of DREAM to DRE3 and DRE4, DREAM did not bind to DRE1 or DRE2 (Fig. 2b,c) . Challenge of the cells with LPS induced uncoupling of DREAM from DRE3 and DRE4, which persisted for 90 min, but DREAM binding 'cycled back' within 180 min ( Fig. 2d,e) , which indicated it was a reversible event. Challenge of cells with TNF also produced similar results ( Fig. 2b-e) .Thus, the function of DREAM in transcriptionally suppressing TNFAIP3 expression involved less binding of DREAM to DRE3 and DRE4, followed by time-dependent restoration of binding to the same domain(s).
Next, to address a possible coordinating role of the overlapping E-box sequence associated with DRE3 in regulating the transcription of TNFAIP3 (Fig. 2a) , we studied the transcription factor USF1, the dominant E-box-binding protein involved in initiating transcription of this gene 8 (Fig. 2f) . To investigate whether USF1 was essential for regulating TNFAIP3 transcription 8 , we next silenced USF1 expression in human umbilical vein endothelial cells and measured A20 expression. Knockdown of USF1 prevented TNF-induced A20 expression (Fig. 2g) . These results showed that DREAM functioned basally to repress transcription of TNFAIP3, but in response to inflammatory stimuli, DREAM dissociated from the DREs, and USF1 bound to the DRE3 E-box to signal TNFAIP3 transcription.
To address whether DREAM also represses the mouse gene encoding A20 (Tnfaip3), we analyzed the Tnfaip3 promoter sequence and observed that this promoter had a DRE site downstream of the TSS in intron 1 and two additional DRE sites upstream of the TSS (Fig. 3a) . Similar to DRE3 of TNFAIP3, DRE2 of Tnfaip3 had an overlapping E-box sequence (Fig. 3a) . We observed that in basal conditions, DREAM bound mainly to the DRE3 domain of the Tnfaip3 promoter and, to a lesser extent, to DRE2 (Fig. 3b-d) .
As expected, we did not find DREAM binding in Dream −/− cells ( Fig. 3b-d) . The binding of DREAM to DRE2 and DRE3 decreased after LPS challenge in a time-dependent manner in wild-type macrophages, as noted for the human cells above, and returned to baseline by 90 min (Fig. 3c,d) . We also observed a positive correlation between the amount of DREAM protein in the nucleus and the binding of DREAM to the DREs (Supplementary Fig. 2a) . npg Since DRE2 in the Tnfaip3 promoter overlapped with the E-box, we assessed the interaction between the DRE2 E-box and USF1. The binding of USF1 to the DRE2 E-box increased maximally within 90 min of challenge with LPS (Fig. 3e) , similar to the results obtained above for human cells showing temporal binding of USF1 to the DRE3 E-box of TNFAIP3 (Fig. 2f) . USF1 bound to the DRE2 E-box of Tnfaip3 in basal conditions in Dream −/− macrophages (Fig. 3e) , which indicated a role for such binding in mediating the persistent Tnfaip3 transcription in the absence of the repressive effect of DREAM. The binding of USF1 to the DRE E-box increased in Dream −/− macrophages until it peaked, at 90 min after the LPS challenge, at the same level as in wild-type cells (Fig. 3e) ; this indicated that USF1 continued to bind to the Tnfaip3 promoter in the absence of DREAM binding. These findings collectively demonstrated that similar to the results obtained for TNFAIP3, DREAM repressed Tnfaip3 transcription by binding to DREs, whereas the binding of USF1 to the DRE-associated E-box domain in response to inflammatory stimuli promoted Tnfaip3 transcription. Thus, these results analyzing the promoter of the gene encoding A20 suggested a model for the regulation of transcription of this gene by the coordinated actions of DREAM and USF1 (Supplementary Fig. 2b ).
DREAM modulates A20 expression during inflammation
We observed that DREAM protein was expressed in variety of cells involved in inflammation, including lung endothelial cells (LECs), PMNs and bone marrow-derived macrophages (BMDMs) of mice ( Fig. 4a-c) . There was approximately threefold higher expression of A20 protein in LECs, PMNs and BMDMs from Dream −/− mice than in their wild-type counterparts (Fig. 4a-c) consistent with the role of DREAM in suppressing Tnfaip3 transcription in these cells (as reported above). As LPS-induced acute lung injury was much less in Dream −/− mice than in their wild-type counterparts (Fig. 1) , we next investigated the possibility that augmented A20 expression in these mice was responsible for the dimished lung-injury response. Challenge with LPS induced three-to fourfold higher A20 expression in Dream −/− lungs than in wild-type lungs (Fig. 4d) . DREAM represses expression of the transcription factor c-Fos by binding to DREs in the Fos promoter 1 . As a positive control, we assessed LPS-induced c-Fos expression in wild-type and Dream −/− mice. We observed that c-Fos expression was higher in the lungs of LPS-treated Dream −/− mice than in their wild-type counterparts (Supplementary Fig. 3 ), which indicated that DREAM deficiency augmented the expression of genes that are targets of DREAM. Here we studied DREAM signaling in endothelial cells, as we found the role of DREAM in these cells was essential for inflammatory lung injury (Supplementary Fig. 1) . At 48 h after siRNA delivery, we observed >80% less A20 protein in Dream −/− mice Knockdown of A20 restores inflammation in Dream −/− mice To address the causal role of the augmented A20 expression noted in Dream −/− mice ( Fig. 4a-d ) in mediating their considerably diminished inflammatory lung-injury response (Fig. 1) , we silenced A20 expression in lung vascular endothelial cells in vivo through the use of given injection of A20-specific siRNA than in Dream −/− mice given injection of either saline or nontargeting siRNA with a scrambled sequence (Scr-siRNA) (Fig. 4e) . ICAM-1 expression induced by LPS in Dream −/− mice given injection of A20-specific siRNA and treated with LPS was significantly greater than that of their Dream −/− counterparts given injection of either saline or Scr-siRNA (Fig. 4f,g ). Also, PMN sequestration (assessed by MPO activity) was greater in the lungs of Dream −/− mice given injection of A20-specific siRNA than in their Dream −/− counterparts given injection of either saline or Scr-siRNA (Fig. 4h) . Thus, the upregulated A20 expression in LECs seen in Dream −/− mice was required for the mitigation of inflammatory lung injury.
DREAM promotes kinase TAK1-mediated NF-kB activation
We next addressed the mechanisms by which the DREAM-induced inhibition of A20 expression mediated inflammatory lung injury. As A20 cleaves K63-linked polyubiquitin chains in TRAF2 and TRAF6 to prevent TAK1 kinase activity [15] [16] [17] [18] [19] [20] [21] and the subsequent activation of NF-κB [15] [16] [17] [18] [19] [20] [21] , we focused on TNF-induced activation of both TAK1 and downstream IKK complexes in LECs obtained from wild-type and Dream −/− mice. We observed time-dependent TNF-induced phosphorylation of IKKβ in wild-type-LECs, but this effect was suppressed in Dream −/− LECs (Fig. 5a) . We next investigated the role of DREAM in mediating the expression of IκBα on the basis of the proposal that NF-κB signaling is required for IκBα expression and that IκBα, in a negative feedback manner, inhibits the activation of NF-κB 9, 10 . We observed that basal expression of IκBα was significantly lower in LECs from Dream −/− mice than in their wild-type counterparts (Fig. 5b) . TNF challenge elicited time-dependent increases in IκBα transcripts (Fig. 5c) and IκBα protein (Fig. 5b) in wild-type LECs. Those responses were abrogated in Dream −/− LECs (Fig. 5b,c) . To address whether activation of TAK1 was also suppressed in Dream −/− LECs, we treated LECs from wild-type and Dream −/− mice with TNF and measured the phosphorylation of TAK1 (ref. 30 ). Here we observed a time-dependent increase in the phosphorylation of TAK1 in wild-type LECs but not in Dream −/− LECs in response to TNF (Fig. 5d) . To determine whether the suppressed activation of IKK in Dream −/− LECs was the result of enhanced A20 expression itself, we did a 'rescue' experiment in which we expressed wild-type DREAM or mutant DREAM unable to bind DNA in Dream −/− LECs. We observed that wild-type-DREAM interacted with TNFAIP3 DRE4 sequence, but the mutant DREAM did not (data not shown). Next, we observed that expression of wild-type DREAM in Dream −/− LECs restored the activation of IKK complexes in response to TNF, but expression of the mutant DREAM did not (Fig. 5e) .
Since TAK1 lies upstream of signaling via the mitogen-activated protein kinases (MAPKs) Jnk and p38 (ref. 30) , we confirmed the role of DREAM in regulating the activation of TAK1 by also assessing the activation of Jnk and p38. TNF-induced phosphorylation of both Jnk and p38 was much lower in Dream −/− LECs than in wild-type LECs (Fig. 6a,b) . To address whether the diminished phosphorylation of those kinases was the result of the higher A20 expression noted in Dream −/− mice, we silenced A20 and found that TNF-induced p38 phosphorylation was restored in in Dream −/− LECs in which A20 was knocked down (Fig. 6c) . In further support of those findings, we observed much lower expression of transcripts encoding MCP-1 and ICAM-1 in Dream −/− LECs in response to TNF challenge than in their wild-type counterparts (Fig. 6d) ; in contrast, A20 expression was augmented in Dream −/− LECs (Fig. 6e) .
Next we studied the role of DREAM in regulating endotoxininduced NF-κB signaling. A20 protein expression was increased to a greater extent in BMDMs from Dream −/− mice than in their wildtype counterparts (Fig. 4c) . To address the functional relevance of the enhanced A20 expression in the endotoxin response, we studied the activation of TAK1 and IKK in macrophages from Dream −/− and wild-type mice following LPS challenge. As in the studies reported above, the LPS-induced activation of TAK1 and IKK was much lower and delayed in Dream −/− cells relative to that in wild-type cells (Supplementary Fig. 4a,b) . These results supported the proposal that augmented A20 expression restricted TAK1-mediated activation of IKK and MAPKs in Dream −/− cells.
DREAM regulates A20 targets that mediate NF-kB signaling We then set out to determine the consequence of DREAM-induced downregulation of A20 in mediating the activation of NF-κB (Fig. 1) . For this, we evaluated the expression of A20 targets in lungs of Dream −/− and wild-type mice. The expression of TRAF2 and TRAF6 (Fig. 7a) , RIP1 and RIP2 (Fig. 7a), IκBα (Fig. 7a) and IKKγ (Fig. 7b) was suppressed in Dream −/− mouse lungs relative to the expression in wild-type mouse lungs. However, expression of IKKα and IKKβ was unaffected (Fig. 7b) . Next we assessed the expression of NF-κB proteins in the lungs of Dream −/− and wild-type mice. The expression of p65-RelA was not different in Dream −/− mouse lungs versus wild-type mouse lungs (Fig. 7c) , whereas the expression of NF-κB1, NF-κB2, RelB and c-Rel was suppressed in Dream −/− mouse lungs (Fig. 7c) . Also, the expression of TRAF2 and TRAF6, RIP1 and RIP2, IKKγ, IκBα and NF-κB proteins (NF-κB1, NF-κB2, RelB, and c-Rel) was lower in Dream −/− LECs than in wild-type LECs (Fig. 7d) . Next we measured the expression of mRNA encoding those NF-κB signaling components by quantitative RT-PCR. Expression of mRNA encoding RIP2 and TRAF2 was much lower in the lungs of Dream −/− mice than in their wild-type counterparts (Supplementary Fig. 5 ), whereas the expression of mRNA encoding RIP1, TRAF6, NEMO, NF-κB1, NF-κB2, RelB and c-Rel was not altered in lungs from Dream −/− mice relative to that in lungs from wild-type mice (Supplementary Fig. 5 ).
To address whether the lower expression of NF-κB signaling components noted in Dream −/− mice was affected by A20, we did 'rescue' experiments in which we ectopically expressed wild-type DREAM or the DNA-binding-defective mutant DREAM in LECs from Dream −/− mice. In this study, expression of wild-type DREAM suppressed the expression of A20 as well as that of c-Fos (another DREAM-regulated protein 1 ) in Dream −/− LECs, but expression of the mutant DREAM did not (Fig. 8) . Expression of wild-type DREAM restored the expression of A20 targets and NF-κB signaling components (except RIP2) in LECs from Dream −/− mice; however, expression of the mutant
c-fos
RelB c-Rel npg DREAM did not produce this result (Fig. 8) . These findings together demonstrated that DREAM-mediated suppression of A20 expression was responsible for activating NF-κB signaling and the NF-κB target genes responsible for inflammatory lung injury. On the basis of our results, we propose a model for the mechanism whereby DREAM regulates A20 expression and thereby regulates the inflammatory NF-κB signaling pathways (Supplementary Fig. 6 ).
DISCUSSION
Our results here have demonstrated a proinflammatory function of the transcription repressor DREAM and its interaction with the transcription activator USF1 in the mechanism of the expression of the deubiquitinase A20 and the subsequent 'tuning' of NF-κB activity. DREAM has been shown to be important in the spinal cord in mediating the sensation of pain 4, 5 . Mice lacking DREAM (Dream −/− ) have increased prodynorphin mRNA and dynorphin A peptides in the spinal cord and diminished pain sensation 4 . Here we found that Dream −/− mice failed to develop inflammatory lung injury in response to sepsis as a result of USF1-mediated expression of A20, and thereby the downstream inhibition of TAK1-mediated activity and signaling by NF-κB. DREAM bound constitutively to DRE3 and DRE4 in the human TNFAIP3 promoter. DREAM binding decreased for 90 min after exposure to LPS or TNF but returned to baseline within 180 min. The cyclic nature of the DREAM-binding response was mirrored by binding of the A20-transcription activator USF1 to the DRE3 Ebox; that is, binding of USF1 functioned to induce transcription of TNFAIP3. A similar pattern emerged for the mouse Tnfaip3 promoter, which suggested a well-conserved mechanism of coordinated regulation of transcription of the gene encoding A20 by DREAM-USF1. The reciprocal function of DREAM and USF1 in regulating such expression is consistent with the proposal that binding of USF1 to the E-box sequence on the promoter of the gene encoding A20 is important for mediating initiation of the transcription of that gene 8 .
We observed that in Dream −/− mice, in which binding of USF1 to the Tnfaip3 promoter remained intact, treatment with endotoxin resulted in lower ICAM-1 expression and sequestration of PMNs in lungs and normal lung vascular barrier function, compared with that of wild-type mice. The Dream −/− mice also showed much less generation of the NF-κB-transcribed proinflammatory mediators IL-6, MCP-1 and TNF and displayed enhanced survival in a CLP model of severe polymicrobial sepsis, results consistent with augmented A20 expression and decreased NF-κB activation in these mice. Therefore, inactivation of DREAM signaling had an indispensible anti-inflammatory function.
As DREAM expressed in hematopoietic cells 6, 7 as well as in endothelial cells may be essential for the mechanism of inflammatory lung injury, we addressed whether DREAM deficiency was responsible for the proinflammatory role of DREAM we identified in Dream −/− mice. We observed that the sequestration of PMNs in lungs, lung production of MCP-1, IL-6, and TNF and lung vascular ICAM-1 expression in chimeras generated by the transplantation of wild-type-mice bone marrow cells into Dream −/− mice was similar to that of Dream −/− mice. Those findings ruled out the possibility of a chief role for DREAM expression in hematopoietic cells in the mechanism of the inflammatory lung injury response. However, they were consistent with published results showing that selective expression of the degradation-resistant form of NF-κB in the vascular endothelium prevents inflammation in mice 31 . Our results suggested that the proinflammatory role of DREAM identified in Dream −/− mice was probably the result of DREAM expressed by endothelial cells.
Since inflammatory lung injury was considerably diminished in Dream −/− mice, we investigated whether augmented A20 expression was responsible for mediating the response. We silenced A20 expression in lung vascular endothelial cells by liposome-mediated delivery of A20-specific siRNA 28, 29 . We found that ICAM-1 expression and sequestration of PMNs in the lungs induced by LPS challenge of Dream −/− mice treated with A20-specific siRNA were significantly greater than that of Dream −/− mice treated with Scr-siRNA. Thus, A20 expression in the LECs of Dream −/− mice was required and sufficient to reestablish the inflammatory lung-injury response in these mice.
With studies of LECs from Dream −/− mice, we demonstrated that the persistent A20 expression in these mice interfered with phosphorylation of TAK1 and thus downstream activation of IKKβ and NF-κB. To assess the functional relevance of this finding, we did a crucial 'rescue' experiment in which we expressed wild-type DREAM or mutant DREAM that was unable to bind to DREs in Dream −/− LECs. In this study, expression of wild-type DREAM in Dream −/− cells restored IKK activation in response to TNF, but expression of the mutant DREAM did not. These studies demonstrated a key role for DREAM and its relationship with USF1 described above in regulating the activation of TAK1-mediated NF-κB signaling.
Because DREAM and USF1 function through modulating A20 expression, we also assessed the expression of various constituents of the NF-κB signaling pathway that as a consequence might be altered by A20 expression. We observed that expression of p65-RelA, IKKα and IKKβ was similar in wild-type and Dream −/− mice. A likely explanation of that finding is that those factors are not transcriptionally regulated by NF-κB 32 . However, we found that the expression of other NF-κB signaling components, including TRAF2, TRAF6, RIP1, RIP2, IκBα, IKKγ, NF-κB1, NF-κB2, RelB and c-Rel, was downregulated in Dream −/− mice. The expression of mRNA encoding TRAF2 and RIP2 was substantially lower in Dream −/− mice than in wild-type mice. Until now, the transcription mechanisms of TRAF2 expression have not been identified, to our knowledge. Our promoter analysis revealed the presence of multiple binding sites for the transcription factor AP-1 in both human and mouse genes encoding TRAF2 (data not shown). It is known that NF-κB signaling mediates the transcription of both the human and mouse genes encoding RIP2 (ref. 33) . A20 restricts the activation of IKK and MAPK (MAPK signaling is essential for AP-1 activation 34 ) by blocking TAK1 function [15] [16] [17] [18] [19] [20] [21] ; therefore, the enhanced A20 expression seen in Dream −/− cells probably prevented the transcription of genes encoding TRAF2 and RIP2 by this mechanism. A20 activity also decreased the expression of NF-κB signaling components through proteosomal pathway, which involves A20-mediated deubiquitination of K63-linked ubiquitin chains followed by ubiquitination of K48-linked ubiquitin chains on the target molecules 20 . Thus, it is possible that lower expression of NF-κB signaling components such as TRAF6 and RIP1 may be the result of constitutive A20-mediated proteosomal degradation of such molecules in Dream −/− cells.
Our findings collectively support the proposal of a key role for USF1-mediated enhanced A20 expression in Dream −/− mice in inhibiting TAK1-mediated signaling. Our findings suggest that the reciprocal relationship between DREAM and USF1 functions as a 'rheostat' that regulates A20 expression and thus enables 'fine tuning' of NF-κB signaling. The anti-inflammatory result of the deletion of DREAM described here would suggest that targeting DREAM might be a potentially useful therapeutic strategy in inflammatory diseases such as acute lung injury.
METHODS
Methods and any associated references are available in the online version of the paper. 
